| Market Cap | 21.24M | P/E | - | EPS this Y | 28.20% | Ern Qtrly Grth | - |
| Income | -14.74M | Forward P/E | -2.01 | EPS next Y | 35.40% | 50D Avg Chg | -19.00% |
| Sales | 8.99M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -51.00% |
| Dividend | N/A | Price/Book | 25.76 | EPS next 5Y | - | 52W High Chg | -85.00% |
| Recommedations | 2.70 | Quick Ratio | 0.93 | Shares Outstanding | 14.28M | 52W Low Chg | 10.00% |
| Insider Own | 38.80% | ROA | -115.77% | Shares Float | 7.12M | Beta | 1.54 |
| Inst Own | 18.68% | ROE | - | Shares Shorted/Prior | 309.22K/238.31K | Price | 2.55 |
| Gross Margin | 58.84% | Profit Margin | -163.95% | Avg. Volume | 47,450 | Target Price | 5.25 |
| Oper. Margin | -218.77% | Earnings Date | Aug 12 | Volume | 34,909 | Change | -3.41% |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
| Cantor Fitzgerald | Neutral | Apr 10, 24 |
| Cantor Fitzgerald | Neutral | Apr 1, 24 |
| Cantor Fitzgerald | Neutral | Sep 26, 23 |
| Alliance Global Partners | Buy | Aug 22, 23 |
| Cantor Fitzgerald | Neutral | May 17, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Merchant Minh Hoang | Secretary & General.. Secretary & General Counsel | Dec 06 | Sell | 3.37 | 980 | 3,303 | 12/08/23 | |
| Sandford Nicole | President & CEO President & CEO | Dec 06 | Buy | 3.36 | 5,000 | 16,800 | 58,703 | 12/06/23 |
| Hombeck Torsten | Chief Financial Offi.. Chief Financial Officer | Sep 08 | Buy | 4.3 | 2,246 | 9,658 | 3,000 | 09/12/23 |
| Fralick Celeste Rachelle | Director Director | Jul 24 | Buy | 3.98 | 754 | 3,001 | 12,032 | 07/26/23 |
| Vos Ellen O'Connor | Director Director | Jul 24 | Buy | 3.98 | 3,769 | 15,001 | 32,878 | 07/26/23 |
| SCHULER JACK W | 10% Owner 10% Owner | Jul 24 | Buy | 2.75 | 181,800 | 499,950 | 1,883,656 | 07/25/23 |
| Cavanaugh Stefanie L. | Director Director | Jul 24 | Buy | 3.98 | 6,281 | 24,998 | 34,904 | 07/25/23 |
| Sandford Nicole | President & CEO President & CEO | Jul 24 | Buy | 3.98 | 12,563 | 50,001 | 134,665 | 07/25/23 |
| Phan Ryan Thinh | CSO & COO CSO & COO | Jul 24 | Buy | 3.98 | 628 | 2,499 | 3,939 | 07/25/23 |
| Parnell Winfred | Director Director | Jul 24 | Buy | 3.98 | 6,281 | 24,998 | 31,513 | 07/25/23 |
| Merchant Minh Hoang | General counsel and.. General counsel and secretary | Jul 24 | Buy | 1.99 | 754 | 1,500 | 980 | 07/25/23 |
| Jordan Veronica GH | Director Director | Jul 24 | Buy | 3.98 | 3,769 | 15,001 | 34,575 | 07/24/23 |
| Hombeck Torsten | Chief Financial Offi.. Chief Financial Officer | Jul 24 | Buy | 3.98 | 754 | 3,001 | 754 | 07/24/23 |
| Herchuk Jannie Prestridge | Director Director | Jul 24 | Buy | 3.98 | 8,794 | 35,000 | 23,833 | 07/24/23 |
| Palmieri Valerie Barber | Executive Chair Executive Chair | May 16 | Buy | 0.5664 | 43,994 | 24,918 | 267,088 | 05/18/22 |
| Sandford Nicole | President and CEO President and CEO | May 16 | Buy | 0.7642 | 98,000 | 74,892 | 136,160 | 05/17/22 |